Pancreatic Cancer News and Research

RSS

Pancreatic cancer is the fourth leading cause of all cancer deaths in the United States and the third leading cause of cancer deaths in individuals ages 40 to 60. Approximately 37,000 Americans are diagnosed with pancreatic cancer each year, and, each year, approximately the same number die from it. Often, pancreatic cancer is found too late for surgical intervention, and chemotherapy and radiation treatments have little effect.

Functional genomics provide improved drug discovery

Functional genomics and proteomics have been quite successful in identifying functions of potential therapeutic targets such as encoded proteins.

20 Apr 2004

Cinnamon's role as an insulin substitute in type II diabetes

Cinnamon may be more than a spice – it may have a medical application in preventing and combating diabetes. Cinnamon may help by playing the role of an insulin substitute in type II diabetes, according to cellular and molecular studies at the University of California, Santa Barbara, Iowa State University and the U.S. Department of Agriculture.

14 Apr 2004

Oral chemotherapy agent Orathecin™ (rubitecan) capsules accepted by FDA for filing

SuperGen Inc. announced today that the Food and Drug Administration (FDA) has officially accepted the Orathecin™ (rubitecan) capsules’ New Drug Application (NDA) for filing. Orathecin, an investigational anticancer compound, is an oral chemotherapy agent that has been investigated as a treatment for pancreatic cancer patients who have failed at least one prior chemotherapy.

26 Mar 2004

Chemotherapy offers new hope for pancreatic cancer patients

Chemotherapy after surgery more than doubles survival rates for pancreatic cancer according to new research published today (18 March 2004) in the New England Journal of Medicine. Scientists from the University of Birmingham and the University of Liverpool have carried out a Europe wide study of more than 280 patients over 10 years.

22 Mar 2004